Neuropeptide Y receptor expression in human primary ovarian neoplasms

Laboratory Investigation

Volumn 84, Issue 1, 2004, Pages 71-80

  Körner, Meike ^a   Waser, Beatrice ^a   Reubi, Jean Claude ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adenocarcinoma; Human ovary; NPY receptor; Receptor autoradiography; Sex cord stromal tumor; Tumor targeting

Indexed keywords

INHIBIN; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; PEPTIDE YY; RADIOACTIVE IODINE; TUMOR MARKER;

ANDROBLASTOMA; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DYSGERMINOMA; FIBROMA; GRANULOSA CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; LEYDIG CELL TUMOR; OVARY ADENOCARCINOMA; OVARY TUMOR; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; ADENOMA; CLASSIFICATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GONAD TUMOR; METABOLISM; OVARY; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ADENOMA; AUTORADIOGRAPHY; CELL LINE, TUMOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IODINE RADIOISOTOPES; NEOPLASMS, GONADAL TISSUE; OVARIAN NEOPLASMS; OVARY; PEPTIDE YY; RECEPTORS, NEUROPEPTIDE Y; TUMOR MARKERS, BIOLOGICAL;

EID: 84857504711     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700009     Document Type: Article

References (41)

1. Reubi JC. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med 1997;41:63-70.
2. Kwekkeboom DJ, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704-1713.
3. Krenning EP, Kwekkeboom DJ, Pauwels S, et al. Somatostatin Receptor Scintigraphy. Raven Press: New York, 1995, pp 1-50.
4. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610-616.
5. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12:450-482.
6. Reubi JC, Gugger M, Waser B, et al. Y1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 2001;61:4636-4641.
7. Reubi JC, Gugger M, Waser B. Coexpressed peptide receptors in breast cancers as molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med 2002;29:855-862.
8. Michel MC, Beck-Sickinger A, Cox H, et al. XVI International union of pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 1998;50:143-150.
9. Gehlert DR. Subtypes of receptors for neuropeptide Y: implications for the targeting of therapeutics. Life Sci 1994;55:551-562.
10. Jain MR, Pu S, Kalra PS, et al. Evidence that stimulation of two modalities of pituitary luteinizing hormone release in ovarian steroid-primed ovariectomized rats may involve neuropeptide Y Y1 and Y4 receptors. Endocrinology 1999;140:5171-5177.
11. McDonald JK. Role of neuropeptide Y in reproductive function. Ann NY Acad Sci 1990;611:258-272.
12. Raposinho PD, Broqua P, Pierroz DD, et al. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype. Endocrinology 1999;140:4046-4055.
13. Hall GH, Turnbull LW, Richmond I, et al. Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours. Br J Cancer 2002;87:86-90.
14. Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 1995;36:1846-1853.
15. Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997;57:1377-1386.
16. Nguyen HN, Averette HE, Hoskins W, et al. National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer 1993;72:3007-3011.
17. Segal R, DePetrillo AD, Thomas G. Clinical review of adult granulosa cell tumors of the ovary. Gynecol Oncol 1995;56:338-344.
18. WHO. In: Scully R (ed), World Health Organization International Histological Classification of Tumors. Histological Typing of Ovarian Tumors, 2nd edn. Springer: Berlin, Heidelberg, New York, 1999.
19. Aicher SA, Springston M, Berger SB, et al. Receptor-selective analogs demonstrate NPY/PYY receptor heterogeneity in rat brain. Neurosci Lett 1991;130:32-36.
20. 2 receptor antagonist. Br J Pharmacol 2000;129:1075-1088.
21. 1 receptor antagonist: BIBP3226. Eur J Pharmacol 1994;271:R11-R13.
22. Pelkey TJ, Frierson Jr HF, Mills SE, et al. The diagnostic utility of inhibin staining in ovarian neoplasms. Int J Gynecol Pathol 1998;17:97-105.
23. Riopel MA, Perlman EJ, Seidman JD, et al. Inhibin and epithelial membrane antigen immunohistochemistry assist in the diagnosis of sex cord-stromal tumors and provide clues to the histogenesis of hypercalcemic small cell carcinomas. Int J Gynecol Pathol 1998;17:46-53.
24. Risbridger GP, Schmitt JF, Robertson DM. Activins and inhibins in endocrine and other tumors. Endocr Rev 2001;22:836-858.
25. Cabrele C, Langer M, Bader R, et al. The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats. J Biol Chem 2000;275:36043-36048.
26. Matsuda H, Brumovsky PR, Kopp J, et al. Distribution of neuropeptide Y Y1 receptors in rodent peripheral tissues. J Comp Neurol 2002;449:390-404.
27. Wharton J, Gordon L, Byrne J, et al. Expression of the human neuropeptide tyrosine Y1 receptor. Proc Natl Acad Sci USA 1993;90:687-691.
28. Russel P, Robboy SJ, Anderson MC. The ovaries: normal appearances and non-neoplastic conditions, In: Robboy SJ, Anderson MC, Russel P (eds). Pathology of the Female Reproductive Tract. Churchill Livingstone: London, 2002, pp 475-526.
29. Jorgensen JC, Sheikh SP, Forman A, et al. Neuropeptide Y in the human female genital tract: localization and biological action. Am J Physiol 1989;257: E220-E227.
30. Jorgensen JC. Interaction between norepinephrine, NPY and VIP in the ovarian artery. Peptides 1991;12:831-837.
31. Barreca A, Valli B, Cesarone A, et al. Effects of the neuropeptide Y on estradiol and progesterone secretion by human granulosa cells in culture. Fertil Steril 1998;70:320-325.
32. Kurman RJ, Goebelsmann U, Taylor CR. Steroid localization in granulosa-theca tumors of the ovary. Cancer 1979;43:2377-2384.
33. Gurusinghe CJ, Healy DL, Jobling T, et al. Inhibin and activin are demonstrable by immunohistochemistry in ovarian tumor tissue. Gynecol Oncol 1995:57:27-32.
34. NIH. NIH consensus conference: ovarian cancer. Screening, treatment, and follow-up. NIH consensus development panel on ovarian cancer. JAMA 1995;273:491-497.
35. Hernadi Z, Juhasz B, Poka R, et al. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4′-epidoxorubicin in the treatment of advanced ovarian cancer. Int J Gynaecol Obstet 1988;27:199-204.
36. Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 1985;9:543-569.
37. Gershenson DM, Morris M, Burke TW, et al. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Obstet Gynecol 1996;87:527-531.
38. Langer M, La Bella R, Garcia-Garayoa E, et al. 99mTc-labeled neuropeptide y analogues as potential tumor imaging agents. Bioconjug Chem 2001;12:1028-1034.
39. Chiara S, Merlini L, Campora E, et al. Cisplatin-based chemotherapy in recurrent or high risk ovarian granulosa-cell tumor patients. Eur J Gynaecol Oncol 1993;14:314-317.
40. Shimizu Y, Nagata H, Kikuchi Y, et al. Cytotoxic agents active against mucinous adenocarcinoma of the ovary. Oncol Rep 1998;5:99-101.
41. Langer M, Kratz F, Rothen-Rutishauser B, et al. Novel peptide conjugates for tumor-specific chemotherapy. J Med Chem 2001;44:1341-1348.